MT. KISCO, N.Y., April 17, 2017 -- ImmuDyne, Inc. (OTCQB:IMMD) (“ImmuDyne” or the “Company”), a leader in the development and marketing of OTC healthcare products, has been informed by OTC Markets Group the company will have until May 15, 2017 to file its Annual Report on Form 10K (prior to OTC Markets taking any action with respect to the company).
ImmuDyne currently expects to finalize its financial results and file its Annual Report on Form 10-K with the SEC as soon as practicable and further expects that the financial information contained in the Form 10-K will be consistent in all material respects with the financial results reported in our press release dated March 6, 2017. Based on the review and analysis conducted to date, no material adjustments, restatement or other revisions to previously issued financial statements of the Company are currently expected to be required.
About lmmuDyne
lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. The Company's products include once a day oral intake capsules as well as topical serums and creams for skin application. lmmuDyne also has developed a proprietary natural delivery technology for potential new market opportunities. All of lmmuDyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to lmmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
Contact: ImmuDyne, Inc. Mark McLaughlin: +1-914-714-8901


Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 



